The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BIAF | -95.39% | N/A | N/A | -99% |
| S&P | +13.19% | +87.83% | +13.42% | +70% |
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.45M | -38.5% |
| Gross Profit | $0.39M | -48.5% |
| Gross Margin | 27.00% | -5.3% |
| Market Cap | $3.96M | -85.8% |
| Market Cap / Employee | $0.07M | 0.0% |
| Employees | 57 | -24.0% |
| Net Income | -$5.05M | -152.4% |
| EBITDA | -$2.18M | -19.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $7.67M | 913.7% |
| Accounts Receivable | $0.42M | -67.0% |
| Inventory | 0 | 38.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.28M | -69.7% |
| Short Term Debt | $0.40M | -49.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -162.88% | -62.0% |
| Return On Invested Capital | -70.21% | -69.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.48M | -44.1% |
| Operating Free Cash Flow | -$2.48M | -45.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.45 | 3.30 | -3.83 | -1.31 | -114.69% |
| Price to Sales | 1.41 | 0.48 | 0.90 | 0.47 | -83.07% |
| Price to Tangible Book Value | 395.43 | 287.63 | -216.76 | -0.66 | -100.11% |
| Enterprise Value to EBITDA | -4.85 | -2.07 | -2.82 | 1.76 | -111.98% |
| Return on Equity | -242.4% | -290.9% | -1802.4% | -245.2% | 46.81% |
| Total Debt | $1.50M | $1.33M | $0.67M | $0.68M | -60.40% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
